Lactate and choline metabolites detected in vitro by nuclear magnetic resonance spectroscopy are potential metabolic biomarkers for PI3K inhibition in pediatric glioblastoma

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Al Saffar, Nada M S ^a   Marshall, Lynley V ^a   Jackson, L Elizabeth ^a   Balarajah, Geetha ^a   Eykyn, Thomas R ^a,b   Agliano, Alice ^a   Clarke, Paul A ^a   Jones, Chris ^a   Workman, Paul ^a   Pearson, Andrew D J ^a   Leach, Martin O ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; CHOLINE; CHOLINE KINASE; CHOLINE KINASE ALPHA; GLUCOSE TRANSPORTER 1; GLYCEROPHOSPHORYLCHOLINE; HEXOKINASE; HEXOKINASE ISOENZYME; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE ALPHA; LACTIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOETHANOLAMINE; PHOSPHORYLCHOLINE; PICTILISIB; PROTEIN KINASE B; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CELL CYCLE S PHASE; CELL PROLIFERATION; CHILD; COMPARATIVE STUDY; CONCENTRATION RESPONSE; DRUG RESPONSE; DYNAMIC NUCLEAR POLARIZATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; G1 PHASE CELL CYCLE CHECKPOINT; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; GLUCOSE METABOLISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOME ASSESSMENT; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL (TOPIC); PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PROCEDURES CONCERNING CELLS; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; SIGNAL TRANSDUCTION; TIME SERIES ANALYSIS; ENZYMOLOGY; FLOW CYTOMETRY; IMMUNOBLOTTING; METABOLISM; PROCEDURES; TUMOR CELL LINE;

CELL LINE, TUMOR; CHOLINE; FLOW CYTOMETRY; GLIOBLASTOMA; HUMANS; IMMUNOBLOTTING; LACTIC ACID; MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 84905455338     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103835     Document Type: Article

References (51)

1. Hargrave DR, Zacharoulis S (2007) Pediatric CNS tumors: current treatment and future directions. Expert. Rev. Neurother. 7: 1029-1042. (Pubitemid 47281317)
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114: 97-109. (Pubitemid 47103521)
3. Jones C, Perryman L, Hargrave D (2012) Paediatric and adult malignant glioma: close relatives or distant cousins? Nat. Rev. Clin. Oncol. 9: 400-413.
4. Bjerke L, Mackay A, Nandhabalan M, Burford A, Jury A, et al. (2013) Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN. Cancer Discov. 3: 512-519.
5. Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, et al. (2010) Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J. Clin. Oncol. 28: 3061-3068.
6. Popov S, Jury A, Laxton R, Doey L, Kandasamy N, et al. (2013) IDH1-associated primary glioblastoma in young adults displays differential patterns of tumour and vascular morphology. PLoS. One. 8: e56328.
7. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, et al. (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482: 226-231.
8. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, et al. (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22: 425-437.
9. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352: 987-996. (Pubitemid 40349501)
10. Broniscer A, Chintagumpala M, Fouladi M, Krasin MJ, Kocak M, et al. (2006) Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J. Neurooncol. 76: 313-319.
11. Ruggiero A, Cefalo G, Garre ML, Massimino M, Colosimo C, et al. (2006) Phase II trial of temozolomide in children with recurrent high-grade glioma. J. Neurooncol. 77: 89-94. (Pubitemid 43870566)
12. Gallia GL, Rand V, Siu IM, Eberhart CG, James CD, et al. (2006) PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Molecular Cancer Research 4: 709-714. (Pubitemid 44683311)
13. Gaspar N, Marshall L, Perryman L, Bax DA, Little SE, et al. (2010) MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature. Cancer Res. 70: 9243-9252.
14. Clarke PA, Workman P (2012) Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials. J. Clin. Oncol. 30: 331-333.
15. Shuttleworth SJ, Silva FA, Cecil AR, Tomassi CD, Hill TJ, et al. (2011) Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors. Curr. Med. Chem. 18: 2686-2714.
16. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, et al. (2008) Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr. Opin. Pharmacol. 8: 393-412.
17. Workman P, Aboagye EO, Chung YL, Griffiths JR, Hart R, et al. (2006) Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. Journal Of The National Cancer Institute 98: 580-598. (Pubitemid 43904842)
18. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, et al. (2012) Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 30: 282-290.
19. Lucignani G, De Palma D (2011) PET/CT in paediatric oncology: clinical usefulness and dosimetric concerns. Eur. J. Nucl. Med. Mol. Imaging 38: 179-184.
20. Gadian DG (1995) The information available from NMR. In. NMR and its applications to living systems: New York: Oxford University Press Inc. 29-64.
21. Bulik M, Jancalek R, Vanicek J, Skoch A, Mechl M (2013) Potential of MR spectroscopy for assessment of glioma grading. Clin. Neurol. Neurosurg. 115: 146-153.
22. Murphy PS, Viviers L, Abson C, Rowland IJ, Brada M, et al. (2004) Monitoring Temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy. British Journal Of Cancer 90: 781-786. (Pubitemid 38406586)
23. Nelson SJ (2011) Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI. NMR Biomed. 24: 734-749.
24. Al-Saffar NM, Jackson LE, Raynaud FI, Clarke PA, Ramírez de Molina A, et al. (2010) The Phosphoinositide 3-Kinase Inhibitor PI-103 Downregulates Choline Kinase {alpha} Leading to Phosphocholine and Total Choline Decrease Detected by Magnetic Resonance Spectroscopy. Cancer Res. 70: 5507-5517.
25. Beloueche-Babari M, Jackson LE, Al-Saffar NMS, Eccles SA, Raynaud FI, et al. (2006) Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells. Molecular Cancer Therapeutics 5: 187-196.
26. Haas-Kogan DA, Yount G, Haas M, Levi D, Kogan SS, et al. (1996) p53-dependent G1 arrest and p53-independent apoptosis influence the radiobiologic response of glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 36: 95-103.
27. Takeshita I, Takaki T, Kuramitsu M, Nagasaka S, Machi T, et al. (1987) Characteristics of an established human glioma cell line, KNS-42. Neurol. Med. Chir (Tokyo) 27: 581-587.
28. Bax DA, Little SE, Gaspar N, Perryman L, Marshall L, et al. (2009) Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development. PLoS. One. 4: e5209.
29. Cory AH, Owen TC, Barltrop JA, Cory JG (1991) Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 3: 207-212.
30. Al-Saffar NS, Troy H, Ramírez de Molina A, Jackson LE, Madhu B, et al. (2006) Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in Human Carcinoma models. Cancer Research 66: 427-434. (Pubitemid 43166051)
31. Tyagi RK, Azrad A, Degani H, Salomon Y (1996) Simultaneous extraction of cellular lipids and water-soluble metabolites: Evaluation by NMR spectroscopy. Magnetic Resonance in Medicine 35: 194-200. (Pubitemid 26044386)
32. Hill DK, Orton MR, Mariotti E, Boult JKR, Panek R, et al. (2013) Model Free Approach to Kinetic Analysis of Real-Time Hyperpolarized 13C Magnetic Resonance Spectroscopy Data. PLoS One 8: e71996.
33. Hill DK, Jamin Y, Orton MR, Tardif N, Parkes HG, et al. (2013) 1H NMR and hyperpolarized 13C NMR assays of pyruvate-lactate: a comparative study. NMR Biomed. 26: 1321-1325.
34. Heiss WD, Heindel W, Herholz K, Rudolf J, Bunke J, et al. (1990) Positron emission tomography of fluorine-18-deoxyglucose and image-guided phosphorus-31 magnetic resonance spectroscopy in brain tumors. J. Nucl. Med. 31: 302-310. (Pubitemid 20090797)
35. Peet AC, Arvanitis TN, Leach MO, Waldman AD (2012) Functional imaging in adult and paediatric brain tumours. Nat. Rev. Clin. Oncol. 9: 700-711.
36. Quon H, Brunet B, Alexander A, Murtha A, Abdulkarim B, et al. (2011) Changes in serial magnetic resonance spectroscopy predict outcome in high-grade glioma during and after postoperative radiotherapy. Anticancer Res. 31: 3559-3565.
37. Chung YL, Troy H, Banerji U, Jackson LE, Walton MI, et al. (2003) Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17- demethoxygeldanamycin (17AAG) in human colon cancer models. Journal Of The National Cancer Institute 95: 1624-1633. (Pubitemid 37455930)
38. Lee SC, Marzec M, Liu X, Wehrli S, Kantekure K, et al. (2013) Decreased lactate concentration and glycolytic enzyme expression reflect inhibition of mTOR signal transduction pathway in B-cell lymphoma. NMR Biomed. 26: 106-114.
39. Su JS, Woods SM, Ronen SM (2012) Metabolic consequences of treatment with AKT inhibitor perifosine in breast cancer cells. NMR Biomed. 25: 379-388.
40. Venkatesh HS, Chaumeil MM, Ward CS, Haas-Kogan DA, James CD, et al. (2012) Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. Neuro. Oncol. 14: 315-325.
41. Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism. Nat. Rev. Cancer 11: 85-95.
42. Dang CV (2012) Links between metabolism and cancer. Genes Dev. 26: 877-890.
43. Braccini L, Ciraolo E, Martini M, Pirali T, Germena G, et al. (2012) PI3K keeps the balance between metabolism and cancer. Adv. Biol. Regul. 52: 389-405.
44. Yecies JL, Manning BD (2011) mTOR links oncogenic signaling to tumor cell metabolism. J. Mol. Med. (Berl) 89: 221-228.
45. Kelly CJ, Hussien K, Muschel RJ (2012) 3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition. Nucl. Med. Biol. 39: 986-992.
46. Nguyen QD, Perumal M, Waldman TA, Aboagye EO (2011) Glucose metabolism measured by [18F]fluorodeoxyglucose positron emission tomography is independent of PTEN/AKT status in human colon carcinoma cells. Transl. Oncol. 4: 241-248.
47. Guillard S, Clarke PA, Te-Poele R, Mohri Z, Bjerke L, et al. (2009) Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma. Cell Cycle 8: 443-453.
48. Kurhanewicz J, Vigneron DB, Brindle K, Chekmenev EY, Comment A, et al. (2011) Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. Neoplasia. 13: 81-97.
49. Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, et al. (2003) Increase in signal-to-noise ratio of >10,000 times in liquid-state NMR. Proc. Natl. Acad. Sci. U. S. A 100: 10158-10163. (Pubitemid 37071849)
50. Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PE, Harzstark AL, et al. (2013) Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1-13C]Pyruvate. Sci. Transl. Med. 5: 198ra108.
51. Beloueche-Babari M, Chung YL, Al-Saffar NM, Falck-Miniotis M, Leach MO (2010) Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy. Br. J. Cancer 102: 1-7.